Haptoglobin 2-2 Genotype, Patient, and Graft Survival in Renal Transplant Recipients.

Autor:	Dupont L; 1 Department of Nephrology, Aarhus University Hospital, Aarhus, Denmark., Eide IA; 2 Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; 3 Department of Nephrology, Oslo University Hospital Ullevål, Oslo, Norway., Hartmann A; 2 Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; 4 Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Christensen JH; 5 Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark.; 6 Centre for Cardiovascular Research, Aalborg University Hospital, Aalborg, Denmark., Åsberg A; 2 Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; 7 The Norwegian Renal Registry, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; 8 Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway., Jenssen T; 2 Section of Nephrology, Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.; 9 Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway., Krarup H; 10 Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark., Svensson M; 11 Department of Nephrology, Oslo University Hospital, Akershus University Hospital, Lørenskog, Norway.
Jazyk:	angličtina
Zdroj:	Progress in transplantation (Aliso Viejo, Calif.) [Prog Transplant] 2017 Dec; Vol. 27 (4), pp. 386-391. Date of Electronic Publication: 2017 Sep 22.
DOI:	10.1177/1526924817732020
Abstrakt:	Background: Cardiovascular disease is the leading cause of death in renal transplant recipients. An association between haptoglobin genotype 2-2 and cardiovascular disease has been found in patients with diabetes mellitus and liver transplant recipients. To date, the role of haptoglobin genotype after renal transplantation has not been studied. Methods: In this single-center retrospective cohort study of 1975 adult Norwegian transplant recipients, who underwent transplantation between 1999 and 2011, we estimated the risk of all-cause and cardiovascular mortality and overall and death-censored graft loss for patients with haptoglobin genotype 2-2 compared to genotype 2-1 or 1-1, after adjustment for confounders and competing risks. Results: We found no associations between haptoglobin genotype 2-2 and cardiovascular mortality (subdistributional hazard ratio 1.08, 95% confidence interval 0.78-1.49; P = .63). We also failed to detect any association between haptoglobin 2-2 genotype and all-cause mortality, overall graft loss, and death-censored graft loss. Similar results were found in the subpopulation of transplant recipients with diabetes. Conclusion: In this large cohort of kidney transplant recipients, we could not demonstrate any association between haptoglobin 2-2 genotype and patient or graft survival after renal transplantation.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu